Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.

Clinical pharmacology and therapeutics - 1 Aug 2014

Relling M V, McDonagh E M, Chang T, Caudle K E, McLeod H L, Haidar C E, Klein T, Luzzatto L

Abstract excerpt

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia (AHA) induced by a number of drugs. We provide guidance as to which G6PD genotypes are associated with G6PD deficiency in males and females. Rasburicase is contraindicated in G6PD-deficient patients due to the risk of AHA and possibly methemoglobinemia. Unless preemptive genotyping has established a...

Topics

Animals
Genotype
Glucosephosphate Dehydrogenase Deficiency
Humans
Pharmacogenetics
Urate Oxidase

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24787449
DOI: 10.1038/clpt.2014.97
PMCID: PMC4111801

Genes

G6PD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.PMID 24787449Read ↗

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.Semantic proximity Read ↗

Incorporating genotyping to identify patients with G6PD deficiencySemantic proximity Read ↗

Incorporating G6PD genotyping to identify patients with G6PD deficiency.Semantic proximity Read ↗

Functional Analysis of G6PD Variants Associated With Low G6PD Activity in the All of Us Research ProgramSemantic proximity Read ↗

Functional analysis of G6PD variants associated with low G6PD activity in the All of Us Research ProgramSemantic proximity Read ↗

Glucose-6-phosphate dehydrogenase deficiencySemantic proximity Read ↗

G6<scp>PD</scp> deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsSemantic proximity Read ↗

Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolismSemantic proximity Read ↗

Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.Semantic proximity Read ↗

Recommendations for pharmacogenetic testing in clinical practice guidelines in the USSemantic proximity Read ↗

G6PD deficiency: global distribution, genetic variants and primaquine therapy.Semantic proximity Read ↗

Genetic variants causing G6PD deficiency: Clinical and biochemical data support new WHO classificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.